

SARS-CoV-2 causes a different cytokine response compared to other cytokine storm-causing respiratory viruses in severely ill patients

1 Marton Olbei ^{1,2}, Isabelle Hautefort ¹, Dezso Modos ^{1,2}, Agatha Treveil ^{1,2}, Martina Poletti ^{1,2},
2 Lejla Gul ¹, Claire D Shannon-Lowe ³, Tamas Korcsmaros ^{1,2,*}

3 ¹Earlham Institute, Norwich, UK

4 ²Quadram Institute Bioscience, Norwich, UK

5 ³The University of Birmingham, Birmingham, United Kingdom

6 * **Correspondence:**

7 Corresponding Author: Tamas Korcsmaros

8 tamas.korcsmaros@earlham.ac.uk

9 **Keywords: SARS-CoV-2, coronavirus, influenza, host response, cytokine.**

10

11 **Abstract**

12 **Hyper-induction of pro-inflammatory cytokines, also known as a cytokine storm or cytokine**
13 **release syndrome (CRS) is one of the key aspects of the currently ongoing SARS-CoV-2**
14 **pandemic. This process occurs when a large number of innate and adaptive immune cells are**
15 **activated, and start producing pro-inflammatory cytokines, establishing an exacerbated**
16 **feedback loop of inflammation. It is one of the factors contributing to the mortality observed**
17 **with COVID-19 for a subgroup of patients. CRS is not unique to SARS-CoV-2 infection; it was**
18 **prevalent in most of the major human coronavirus and influenza A subtype outbreaks of the**
19 **past two decades (H5N1, SARS-CoV, MERS-CoV, H7N9). Here, we collected changing**
20 **cytokine levels upon infection with the aforementioned viral pathogens through a**
21 **comprehensive literature search. We analysed published patient data to highlight the conserved**
22 **and unique cytokine responses caused by these viruses. A map of such responses could help**
23 **specialists identify interventions that successfully alleviated CRS in different diseases and**
24 **evaluate whether they could be used in COVID-19 cases.**

25

26 **1 Introduction**

27 The current coronavirus (COVID-19) pandemic has very much focused attention upon this and other
28 viral infectious diseases that the host antiviral immune response is unable to resolve (1–5). Indeed,
29 major efforts are now concentrating on how severe acute respiratory syndrome β -coronavirus 2
30 (SARS-CoV-2) alters normal antiviral immune responses (6–15). SARS-CoV-2 causes a wide range
31 of clinical symptoms from asymptomatic, through mild (fever, persistent cough, loss of taste and
32 smell), to severe inflammation-driven pneumonia resulting in multiple organ failure and ultimately
33 death (9–20). SARS-CoV2 induces an anti-inflammatory response attacking both the upper and

34 lower respiratory tract as well as the gut. The upper respiratory tract infection could cause its high
35 infectivity, while the lower respiratory tract and extrapulmonary symptoms are responsible for its
36 severity. Although SARS-CoV-2 appears to modify host inflammatory defences, similar
37 modifications are also observed in other severe respiratory infections caused by viruses such as
38 influenza A, β -coronaviruses SARS-CoV and MERS-CoV. These agents all constitute a global health
39 threat with colossal economic consequences (21,22).

40 Although these different viruses cause similar clinical symptoms, the pathogenesis may be driven by
41 different triggers, depending upon the virus. Multiple studies have described an exacerbation of the
42 pro-inflammatory host immune response associated with severe forms of the diseases, including
43 cytokine storms, or cytokine release syndrome (CRS) (1–5,9–16). Although CRS usually resolves
44 following completion of the antiviral response, it persists in severe cases leading to tissue damage,
45 multiple organ failure and death in critically-ill patients if the clinical intervention is not rapid. In
46 such cases, concentrations of both pro- and anti-inflammatory cytokines are significantly increased in
47 blood and other tissues, including the type-I interferons (IFN) (IFN- α , - β , - κ , - ε , - τ , - ω and - ζ) (23–
48 26). Type I IFN signalling cascades also attenuate inflammation to avoid tissue damage during viral
49 infection (27). The main effectors of the type-I IFN signalling are IFN- α and IFN- β , which activate
50 other cytokines such as IL-12 and the type II interferon cytokine, IFN- γ (28,29). However, cytokines
51 such as IL-10 block the type-I IFN response. Certain pathogens, including SARS-CoV and MERS-
52 CoV encode proteins that can influence and delay the type-I IFN response leading to various
53 pathologies (30–32). In the case of SARS-CoV, the build-up of activated macrophages in the lungs
54 can cause tissue damage, while MERS-CoV can intensify engagement by neutrophils, leading to an
55 increase in the production of pro-inflammatory cytokines (33,34). Furthermore, Influenza A and
56 coronaviruses infections can trigger increased levels of the type-I interferons IFN- α and IFN- β ,
57 reflecting the normal initiation of this signalling pathway in response to viral infections (9–20,26,34–
58 38). However, in severe infections with SARS-CoV-2, the type-I IFN signalling is impaired,
59 culminating in an altered development of adaptive immunity (9–15,35,39,40)

60 The broadly similar clinical symptoms and the range of disease severity of different respiratory viral
61 infections tend to blur the accuracy of initial diagnosis (41,42), and explain why systemic non-
62 prescription medications are given to patients to initially treat broad symptoms rather than acting on
63 virus-specific parameters (41). Capturing a picture of the immune response triggered in each patient,
64 early enough in infection remains challenging, impairing the adequate prevention of developing the
65 severe form of the disease, consequently to unpredictable CRS. Defining the overlap and/or
66 specificity in the patient immune cytokine signalling across CRS-causing viruses would help
67 clinicians to develop a more tailored treatment strategy for future cases. Recent reviews have
68 attempted to compare diseases caused by influenza A and β -coronaviruses (37,43–47). However,
69 most of these studies have focused on clinical or phylogenetic parameters (virus genome, patient age,
70 transmissibility, fatality rate, creatinine and coagulation amongst others), whilst overlooking
71 mechanistic details relating to host immune responses. To provide mechanistic insight into the role of
72 pro- and anti-inflammatory cytokines into the development of severe disease caused by SARS-CoV,
73 SARS-CoV-2, MERS-CoV and influenza viruses, we need to understand the differences in cytokine
74 responses between the different viruses.

75 To identify the similarities and differences in the cytokine response, we collected and analysed the
76 patterns of cytokine changes caused by these CRS-causing respiratory viruses. By comparing
77 available patient data from the literature, we were able to show i) where similarities lie between the
78 immune responses mounted against these pathogens, ii) what discriminates between influenza A

79 subtypes and coronaviruses, and iii) what are the unique aspects of the currently circulating SARS-
80 CoV-2 virus.

81

82 **3 Methods**

83 **3.1 Literature search**

84 A mass literature search of 98 cytokines (48) was performed in PubMed using PubTator, and in
85 bioRxiv¹ and medRxiv² non-peer reviewed pre-publication repositories (49). This included the
86 commonly studied interleukins, interferons, tumor growth factors and chemokines involved in pro-
87 inflammatory and anti-inflammatory responses - in particular those associated with disease-
88 associated CRS manifestations. Only studies indicating increase or no change in cytokine levels were
89 included. The amplitude of change was not measured, only the presence or absence of it. We focused
90 our study on five important CRS-causing viruses: the two influenza A virus subtypes H5N1 and
91 H7N9 and the three β -coronaviruses SARS-CoV, MERS-CoV and SARS-CoV-2 (Figure 1). We used
92 the names of each virus and the cytokines and chemokines as search terms, e.g. “SARS-CoV-2 +
93 CXCL10” (Figure 1). The collected studies were then screened to retain the studies using only
94 patient-derived data, measured in at least 10 patients. A second pass was done adding “patient” to the
95 search terms, e.g. “SARS-CoV-2 + CXCL10 + patient” in cases where the original search term
96 yielded more than 50 hits. We only considered articles valid if they contained patient-derived data
97 directly; cell line or model organism-based results (and reviews) were excluded. From the main text
98 of the resulting articles, we generated a table containing the presence of the queried cytokines and
99 their direction of change in each disease. We closed the curation on 03/06/2020 (See Supplementary
100 Table S2 for the full list of queried cytokines). The number of discarded articles was estimated using
101 custom python and shell scripts, available in the publication repository.

102 **3.2 Hierarchical clustering**

103 We clustered our data using the *clustermap* function from the python package seaborn with Jaccard
104 distance and complete linkage method (50). We used all cytokine categories as input. The code is
105 available at our GitHub repository³.

106

107 **4 Results**

108 In order to capture as many studies as possible on which to apply the defined inclusion filtering for
109 our work, we started from a list of relevant cytokines found in a textbook source (48) (Figure 1). We
110 only used studies that reported the directional change of measured cytokines. Our curation approach
111 allowed us to highlight shared and differing cytokine responses between influenza A and β -
112 coronaviruses, contributing to further understanding of why SARS-CoV-2 in particular differs so
113 much from influenza A CRS-causing viruses but also from other β -coronaviruses, also capable to
114 inducing a cytokine storm in severe cases.

¹ <https://www.biorxiv.org/>

² <https://www.medrxiv.org/>

³ <https://github.com/NetBiol/Covid19/tree/master/CRS>

115

116 **Figure 1: The literature curation workflow applied in this study.** Publications were considered
117 valid for inclusion into our data collection i) only if they contained patient-derived data (model
118 organisms and cell lines were excluded) and ii) if the study data were collected from cohorts of at
119 least 10 participants per group, iii) and if it included a change in cytokine levels. Total hits to queries
120 in bioRxiv, medRxiv and PubTator shown separately in the second box from the top. 55 publications
121 were selected that matched our curation criteria listed above.

122

123 **4.1 β -coronaviruses and influenza A viruses show marked differences in some cytokine** 124 **responses**

125 Out of the nearly 100 cytokines measured across all initially-collected studies only 38 were retained
126 as matching our criteria (See Methods section; Supplementary Table S1). Only a small group of
127 cytokines was commonly measured for all viruses (CXCL8, IL-6, CXCL10, IL-2, IL-10, IFN- γ ,
128 TNF- α). Across the 55 literature references used here (Figure 1), we first assessed how comparable
129 the number of different cytokines measured in these studies was across the five CRS-causing viruses.
130 Figure 2 shows how variable this number is between virus-specific studies (e.g. 15 for H5N1 and 26
131 for SARS-CoV-2). This variation probably reflects i) the increasing interest developed for CRS-
132 causing pathologies over recent years (26 recent studies reported cytokine measurement for SARS-
133 CoV-2 against only 10 H5N1-related studies), and ii) the increased availability and sensitivity of
134 multiplex detection method.

135 **Figure 2: Number of cytokines measured in the studies retained for each considered CRS-**
136 **causing virus.** Each stacked bar indicates how many cytokines were found at increased levels
137 (yellow) in the patients' blood/solid tissue, not changed (blue) or both increased and not changed
138 across different studies of the same virus (green). The n number shown on the bottom of the bar
139 charts corresponds to the number of articles citing cytokine changes during infection.

140 The influenza A viruses trigger an increase in all cytokine levels measured (Figure 2, red). In
141 contrast, during infection with each of the β -coronaviruses, some cytokines were detected at levels
142 normally found in control groups (blue). This indicates that β -coronaviruses can subvert the immune
143 response, reflecting different kinetics and pathogenesis between the influenza- and coronavirus-
144 associated diseases. Of note, studies of H5N1 infections showed that a few cytokines were increased
145 compared with control groups, no change was observed in other studies (17,51), illustrating the
146 greater complexity of these diseases, probably due to the multifactorial nature of the mechanisms
147 involved.

148

	Cytokines elevated at least in one study (elevated & mixed)
Virus-specific	16
Shared between 2 viruses	5
Shared between 3 viruses	8
Shared between 4 viruses	2
Common to all 5 viruses	5

150 **Table 1: Number of cytokines which were elevated in at least one study.** Cytokines measured in
151 one or more of the virus-induced infections. Mixed observations occur when one or more studies
152 show no change in a cytokine level upon infection, whereas others show an increase.

153 Table 1 shows the number of cytokines whose levels are increasing in one, or two, three, four or all
154 five virus-related infections from the interrogated literature. Only 5 cytokines were modulated
155 regardless of the virus-associated disease concerned, with 20 other cytokines being shared to some
156 degree. Increased levels observed in 16 cytokines were unique to a single virus at a time. It is
157 important to keep in mind the cytokines' amplitude of change is not considered, which can be
158 different between the different diseases, adding to the heterogeneity of those severe respiratory
159 infectious diseases. This backs up the highly complex nature of the associated diseases as well as the
160 past and current struggles to develop efficient vaccines and treatments.

161 To examine the presence of the measured cytokines and directionality of their change, we constructed
162 a heatmap of the included viruses and cytokine responses.

163

164 **4.2 The cytokine response to SARS-CoV-2 sits in between the ones given to other β -** 165 **coronaviruses and influenza A viruses**

166 The cluster analysis of the viruses forms three clusters. SARS-CoV and MERS-CoV comprise the
167 coronavirus cluster, H5N1 and H7N9 form the influenza cluster, while SARS-CoV2 sits in an
168 individual cluster (Figure 3), slightly closer to the two influenza A viruses than to the two β -
169 coronaviruses.

170 **Figure 3. Influenza viruses, SARS-CoV and MERS-CoV, and SARS-CoV2 form separated**
171 **clusters (I-VIII) based on their cytokine response.** Hierarchical clustering is based on Jaccard
172 distance complete linkage.

173 The cluster analysis of cytokines defines eight clusters, based on the direction of their modulation
174 upon infection with each virus. It is important to note that the results of this cluster analysis are
175 biased by the missing information for some cytokines. Bearing this in mind, it is nonetheless worth

176 looking into the detailed patterns of cytokine responses of the various CRS-inducing viruses. The
177 cytokine cluster I includes the pro-inflammatory TNF- α and two anti-inflammatory cytokines IL-2
178 and IL-10. All of them had mixed results in SARS-CoV-2, while encompassing all three categories
179 of results for the other two coronavirus infections, and predominantly increased during influenza
180 infections. Unfortunately, cluster II seems to be restricted to cytokines measured only in H7N9-
181 mediated infections, preventing us from comparing influenza A viruses versus with β -coronaviruses.
182 Clusters III and VI carry the generally increased pro-inflammatory cytokines, which are elevated for
183 almost all of the viruses, but not measured in all of the cases of cluster VI. Among those cytokines
184 are IFN- α and IFN- γ , typical representatives of the general antiviral response (type I and type II
185 interferons), as well as IL-6, one of the most prominent pro-inflammatory cytokines, along various
186 chemokines. Cytokines from Cluster IV measured during coronavirus infections do not fluctuate,
187 while most of them are elevated during influenza infection, e.g. IL-4 and IL-5 upon H7N9 infections.
188 IL-4 is involved in Th2 differentiation, and the Th2 cells can produce IL-5 to mitigate eosinophil
189 infiltration (52). Such differences observed between virus-specific pathologies reflect the strong
190 alterations observed in coronavirus infections, particularly SARS-CoV-2 (53). The cytokines in
191 Cluster VII and VIII do not always respond to SARS-CoV-2: IL-15 and CCL5 (RANTES) are not
192 elevated after SARS-CoV2 infection. IL-15 is involved in natural killer cell differentiation as part of
193 antiviral response (54). Meanwhile, CCL5 mediates eosinophil infiltration which is considered to be
194 involved in the recovery after SARS-CoV infection (55). Clusters II and V contain cytokines
195 measured only in H7N9 and SARS-CoV2, respectively, whereas TGF- β 1 was measured only in
196 SARS-CoV studies in cluster IV.

197 For a subset of pro-inflammatory cytokines, the clustering analysis shows that SARS-CoV-2 induces
198 a similar response to all other viruses (See Cluster III and VI; Figure 3). Its uniqueness lies in the fact
199 that not all of the expected cytokines are elevated, e.g. the ones following an influenza infection such
200 as IL-2, IL-10, TNF- α , IL-4 or IL-5.

201

202 **4.3 Type I interferon signalling is more strongly altered upon infection with SARS-CoV-2** 203 **than in SARS-CoV- or MERS-CoV-infections.**

204 Both type-I and type-II IFNs play an instrumental role in the immune response to viral infection.

205 Our analysis shows early induction of type-I interferons occurs upon H5N1 and H7N9 influenza A
206 infection as well as for the β -coronavirus SARS-CoV and MERS-CoV (26,37,56). However, type-I
207 IFN response is only weakly elicited following a SARS-CoV-2 infection, if at all (39,57, Figure 4).

208

209 **Figure 4: Type I interferon response upon infection with the different CRS-causing viruses.** The
210 measured cytokines in the influenza viruses are increased. In the case of the coronaviruses the
211 response is mixed, not all of the anti-inflammatory cytokines are elevated. Only a fraction of
212 cytokines is depicted for clarity. Yellow for increase in that virus, green for mixed results and blue
213 for no-change.

214

215 Infection with either of the two influenza subtypes seems to increase the levels of measured type-I
216 IFN-relevant cytokines, resulting in an antiviral immune response, with the appropriate cytokines
217 showing elevated levels in all influenza A studies (Figure 4, Supplementary Table S1).

218 The β -coronavirus-mediated responses show a much more variable IFN response: with SARS-CoV,
219 we see that the type-I IFN response is active, including the downstream-activated IL-12 that reflects
220 the involvement of mature dendritic cells. IL-12 also indirectly activates IFN- γ further downstream.
221 IL-10 is not elevated, which potentially prevents the downregulation of the type-I interferon
222 response.

223 In MERS-CoV infections, the type-I IFN response is induced, but not in all cases (58). In some
224 studies, the levels of IL-12 do not increase, in agreement with IFN- γ also staying at low levels. Yet
225 we see the involvement of the (mostly) anti-inflammatory IL-10. However, caution needs to be
226 applied when looking at IL-10 in an inflammation context, as more and more clinical evidence
227 suggests this cytokine displays pro-inflammatory characteristics *in vivo* (59,60).

228 We showed here that SARS-CoV-2-mediated infections are characterized by a clear dysregulation of
229 type-I IFN response, and consequently the downstream cytokine signature such as IL-4, IL-12, IL-2,
230 IL-10 and the downstream type II IFN response (Figure 4).

231

232 **5 Discussion**

233 In this study, we analysed relevant cytokine levels measured in patients infected each with one of five
234 major viral pathogens through a comprehensive literature curation of published patient data. We
235 generated a map of such responses to help specialists identify routes of interventions to successfully
236 alleviate CRS in different diseases, and evaluate whether they could be used in COVID-19 cases.
237 Based on our literature curation, the five investigated viruses cause atypical cytokine responses in
238 severely-ill patients, reported here in Figure 3.

239 The cytokine response during viral infection is a dynamic process, with multiple changes in cytokine
240 levels during the course of the infection. During SARS and MERS infection, a slow initial innate
241 immune response accompanied by the infection of alveolar macrophages leads to increased severity
242 of these lower respiratory tract diseases (61–65). Furthermore, a long-lasting pro-inflammatory
243 cytokine production results in high mortality due to the development of severe conditions such as
244 acute respiratory distress syndrome (ARDS) or acute lung injury (9.5% fatality rate for SARS and
245 34.4% for MERS compared to 2.3% for COVID-19 (44)).

246 Severe SARS patients show particularly low levels of the anti-inflammatory cytokine IL-10 (Figures
247 3, 4) (66). During MERS infection patients develop an expected increased production of IL-10, yet
248 the low levels of IFN- γ -inhibiting IL-4 and IL-2, lead to elevated IFN- γ and the induction of type-II
249 IFN response (Figure 3) (58,67,68). In contrast, during influenza A infection, the antiviral response
250 activates without much delay with the presence of an intact negative feedback loop. Both viruses
251 considered in our curation induce most of the pro- and anti-inflammatory cytokines downstream of
252 type-I interferon response (Figure 3). Although influenza A viruses have effectors that dysregulate
253 IFN-I (e.g. NS1, PB1-F2, polymerase proteins), the IFN-I response is nonetheless sustained, and its
254 excessive activation during severe illness can lead to increased mortality. Furthermore, during H7N9
255 and H5N1 severe infections, TGF- β fails to be activated, contributing to increased pathogenicity (69–
256 71). SARS-CoV-2 stands out from the other β -coronaviruses and influenza A viruses, with a highly

257 perturbed response downstream of Type I IFN signalling, as reflected in the poor balance of
258 measured pro-and anti-inflammatory cytokines (Figures 3 and 4). Of note, IFN- α was found to be
259 increased (similar to the other viruses) only in one small (n=4) patient study, which did not match our
260 inclusion criteria. Type-II IFN- γ was also only increased in patients placed in intensive care units
261 (ICUs) , while it was within normal ranges in other studies (10,72,73).

262 Although the cytokine signalling enabling the reduction of the inflammatory environment is active
263 (Figures 3 and 4), both influenza viruses H5N1 and H7N9 can cause CRS. In severe cases of
264 infection, CRS could result from insufficient production of important cytokines such as TGF- β (71).
265 Furthermore, the presence of impaired and less abundant effector CD4⁺ and CD8⁺ T cells was found
266 to be a characteristic feature accompanying CRS in those diseases. Finally, monocytes, that normally
267 would differentiate from a pro- to anti-inflammatory state with enhanced antigen presentation activity
268 as the infection progresses, remain in a chronic pro-inflammatory activation state, preventing the
269 normal resolution of the host response (16,74,75). In future studies, patient-derived data including the
270 size and activation status of innate and adaptive immune cell populations would help increase the
271 understanding of CRS mechanisms in influenza-mediated diseases.

272 In our study, we found resolution of the pro-inflammatory immune response to be a key difference
273 between coronaviruses (MERS-CoV and SARS-CoV) and influenza viruses (H5N1 and H7N9). Both
274 MERS-CoV and SARS-CoV induce CRS, yet they also appear to impair the normal resolution of the
275 antiviral immune response. In contrast, H5N1 and H7N9 induce high levels of pro- and anti-
276 inflammatory cytokine levels in severe cases leading to an inflammatory cytokines storm, yet leaving
277 the immune system unimpeded to move towards a general a resolution of the antiviral response
278 appears (Figures 3 and 4) (17). However, SARS-CoV-2 induction of the CRS is eventually followed
279 by a resolution of the pro-inflammatory responses in 80% of the cases.

280 One limitation of this study is the lack of anatomical and dynamic dimensions of the cytokine
281 response. Firstly, the set of cytokines measured in the peripheral blood of each patient across the
282 entire disease course or following recovery varied across the studies analysed. Patients were sampled
283 at different stages of the disease, which further adds to the noise observed in the data. Finally,
284 systematic patient-based studies matching our strict curation criteria could not be collected, leaving
285 many gaps in our comparisons (Figure 3, white cells).

286 While confirming many already reported disease traits, our analysis has highlighted several new
287 features that are shared or different between the viral diseases analysed, contributing to filling the gap
288 in the understanding of SARS-CoV2 and other CRS-causing viruses. Blockage of the cytokine
289 response in SARS-CoV2 infection through IL-6 specific antibody has failed during Phase 3
290 randomised clinical trial (NCT04320615), even with promising results in earlier stages (76),
291 suggesting that further mechanistic investigation of the cytokine storms during SARS-CoV-2
292 infection will be needed.

293 The ongoing accumulation of patient-derived large data sets will inform the research community and
294 clinicians of the intricacy of host/virus interactions (77). Here we provided a literature curation of
295 patient-derived data and a comparative map across CRS-causing β -coronaviruses and influenza A
296 viruses, linking shared or specific changing cytokines and interferon signalling alterations to those
297 pathogens.

298

299 **Acknowledgements**

300 We thank the current and past members of the Korcsmaros group and the COVID-19 Disease Map
301 Community for their ideas and support.

302

303 **Funding**

304 M.O., A.T., L.G., and M.P. are supported by the UKRI Biotechnological and Biosciences Research
305 Council (BBSRC) funded Norwich Research Park Biosciences Doctoral Training Partnership (grant
306 numbers BB/M011216/1 and BB/S50743X/1). The work of T.K., D.M., and I.H. was supported by
307 the Earlham Institute (Norwich, UK) in partnership with the Quadram Institute (Norwich, UK) and
308 strategically supported by the UKRI BBSRC UK grants (BB/J004529/1, BB/P016774/1, and
309 BB/CSP17270/1). C.D.S. was supported by MRC MR/N023781/1 and the Histiocytosis Society,
310 USA. T.K. and D.M. were also funded by a BBSRC ISP grant for Gut Microbes and Health
311 BB/R012490/1 and its constituent projects, BBS/E/F/000PR10353 and BBS/E/F/000PR10355.

312

313 **Bibliography**

- 314 1. Luo W, Li Y-X, Jiang L-J, Chen Q, Wang T, Ye D-W. Targeting JAK-STAT Signaling to
315 Control Cytokine Release Syndrome in COVID-19. *Trends Pharmacol Sci.* 2020 Jun 17;41(8):531–
316 43.
- 317 2. Conti P, Ronconi G, Caraffa A, Gallenga C, Ross R, Frydas I, et al. Induction of pro-
318 inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or
319 SARS-CoV-2): anti-inflammatory strategies. *J Biol Regul Homeost Agents.* 2020 Mar 14;34(2).
- 320 3. McGonagle D, Sharif K, O'Regan A, Bridgewood C. The Role of Cytokines including
321 Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease.
322 *Autoimmun Rev.* 2020 Jun;19(6):102537.
- 323 4. Omarjee L, Janin A, Perrot F, Laviolle B, Meilhac O, Mahe G. Targeting T-cell senescence
324 and cytokine storm with rapamycin to prevent severe progression in COVID-19. *Clin Immunol.* 2020
325 May 13;216:108464.
- 326 5. Rahmati M, Moosavi MA. Cytokine-targeted therapy in severely ill COVID-19 patients:
327 Options and cautions. *EJMO.* 2020; 4(2): 179-181
- 328 6. Bouhaddou M, Memon D, Meyer B, White KM, Rezelj VV, Correa Marrero M, et al. The
329 Global Phosphorylation Landscape of SARS-CoV-2 Infection. *Cell.* 2020 Aug 6;182(3):685-712.e19.
- 330 7. Totura AL, Baric RS. SARS coronavirus pathogenesis: host innate immune responses and
331 viral antagonism of interferon. *Curr Opin Virol.* 2012 Jun;2(3):264–75.
- 332 8. Nelemans T, Kikkert M. Viral innate immune evasion and the pathogenesis of emerging RNA
333 virus infections. *Viruses.* 2019 Oct 18;11(10).
- 334 9. Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlöber HA, Schlaak M,
335 et al. Cytokine release syndrome. *J Immunother Cancer.* 2018 Jun 15;6(1):56.

- 336 10. Pedersen SF, Ho Y-C. SARS-CoV-2: a storm is raging. *J Clin Invest*. 2020 May
337 1;130(5):2202–5.
- 338 11. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the
339 cytokine storm. *Microbiol Mol Biol Rev*. 2012 Mar;76(1):16–32.
- 340 12. Huang K-J, Su I-J, Theron M, Wu Y-C, Lai S-K, Liu C-C, et al. An interferon-gamma-related
341 cytokine storm in SARS patients. *J Med Virol*. 2005 Feb;75(2):185–94.
- 342 13. Neumann J, Prezzemolo T, Vanderbeke L, Roca CP, Gerbaux M, Janssens S, et al. An open
343 resource for T cell phenotype changes in COVID-19 identifies IL-10-producing regulatory T cells as
344 characteristic of severe cases. *medRxiv*. 2020 Jun 2;doi:
345 <https://doi.org/10.1101/2020.05.31.20112979>
- 346 14. Liu Y, Zhang C, Huang F, Yang Y, Wang F, Yuan J, et al. Elevated levels of plasma
347 cytokines in COVID-19 reflect viral load and lung injury. *Natl Sci Rev*. 2020 Mar 9;
- 348 15. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-
349 19. *J Infect*. 2020 Apr 10;80(6):607–13.
- 350 16. Wauters E, Van Mol P, Garg AD, Jansen S, Van Herck Y, Vanderbeke L, et al.
351 Discriminating Mild from Critical COVID-19 by Innate and Adaptive Immune Single-cell Profiling
352 of Bronchoalveolar Lavages. *BioRxiv*. 2020 Jul 1; doi: <https://doi.org/10.1101/2020.07.09.196519>
- 353 17. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJD, Chau TNB, et al. Fatal
354 outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. *Nat*
355 *Med*. 2006 Oct;12(10):1203–7.
- 356 18. Zeng H, Belser JA, Goldsmith CS, Gustin KM, Veguilla V, Katz JM, et al. A(H7N9) virus
357 results in early induction of proinflammatory cytokine responses in both human lung epithelial and
358 endothelial cells and shows increased human adaptation compared with avian H5N1 virus. *J Virol*.
359 2015 Apr;89(8):4655–67.
- 360 19. Payne B, Bellamy R. Novel respiratory viruses: what should the clinician be alert for? *Clin*
361 *Med*. 2014 Dec;14 Suppl 6:s12–6.
- 362 20. To KKW, Hung IFN, Chan JFW, Yuen K-Y. From SARS coronavirus to novel animal and
363 human coronaviruses. *J Thorac Dis*. 2013 Aug;5 Suppl 2:S103–8.
- 364 21. Wei P, Cai Z, Hua J, Yu W, Chen J, Kang K, et al. Pains and Gains from China’s Experiences
365 with Emerging Epidemics: From SARS to H7N9. *Biomed Res Int*. 2016 Jul 20;2016:5717108.
- 366 22. Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A Novel Coronavirus
367 Emerging in China - Key Questions for Impact Assessment. *N Engl J Med*. 2020 Feb 20;382(8):692–
368 4.
- 369 23. Kalliolias GD, Ivashkiv LB. Overview of the biology of type I interferons. *Arthritis Res Ther*.
370 2010 Apr 14;12 Suppl 1:S1.

- 371 24. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, et al. Interferons at
372 age 50: past, current and future impact on biomedicine. *Nat Rev Drug Discov*. 2007 Dec;6(12):975–
373 90.
- 374 25. Brassard DL, Grace MJ, Bordens RW. Interferon- α as an immunotherapeutic protein. *Journal*
375 *of Leukocyte Biology*. 2002 Apr 1; 71: 565-581.
376
- 377 26. Mi Z, Ma Y, Tong Y. Avian influenza virus H5N1 induces rapid interferon-beta production
378 but shows more potent inhibition to retinoic acid-inducible gene I expression than H1N1 in vitro.
379 *Virol J*. 2012 Aug 3;9:145.
- 380 27. Lee AJ, Ashkar AA. The dual nature of type I and type II interferons. *Immunol*. 2018 Sep
381 11;9:2061.
- 382 28. Kang S, Brown HM, Hwang S. Direct Antiviral Mechanisms of Interferon-Gamma. *Immune*
383 *Netw*. 2018 Oct 17;18(5):e33.
- 384 29. Bhardwaj N, Seder RA, Reddy A, Feldman MV. IL-12 in conjunction with dendritic cells
385 enhances antiviral CD8+ CTL responses in vitro. *J Clin Invest*. 1996 Aug 1;98(3):715–22.
- 386 30. Guix S, Pérez-Bosque A, Miró L, Moretó M, Bosch A, Pintó RM. Type I interferon response
387 is delayed in human astrovirus infections. *PLoS ONE*. 2015 Apr 2;10(4):e0123087.
- 388 31. Murira A, Lamarre A. Type-I Interferon Responses: From Friend to Foe in the Battle against
389 Chronic Viral Infection. *Front Immunol*. 2016 Dec 19;7:609.
- 390 32. Channappanavar R, Fehr AR, Zheng J, Wohlford-Lenane C, Abrahante JE, Mack M, et al.
391 IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes.
392 *The Journal of Clinical Investigation*. 2019 Sep 3;
- 393 33. Channappanavar R, Fehr AR, Zheng J, Wohlford-Lenane C, Abrahante JE, Mack M, et al.
394 IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes.
395 *The Journal of Clinical Investigation*. 2019 Sep 3;
- 396 34. Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, et al. Dysregulated
397 Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in
398 SARS-CoV-Infected Mice. *Cell Host Microbe*. 2016 Feb 10;19(2):181–93.
- 399 35. Ma Y, Wang C, Xue M, Fu F, Zhang X, Li L, et al. The Coronavirus Transmissible
400 Gastroenteritis Virus Evades the Type I Interferon Response through IRE1 α -Mediated Manipulation
401 of the MicroRNA miR-30a-5p/SOCS1/3 Axis. *J Virol*. 2018 Nov 15;92(22).
- 402 36. Califano D, Furuya Y, Roberts S, Avram D, McKenzie ANJ, Metzger DW. IFN- γ increases
403 susceptibility to influenza A infection through suppression of group II innate lymphoid cells.
404 *Mucosal Immunol*. 2018;11(1):209–19.
- 405 37. Yao Z, Zheng Z, Wu K, Junhua Z. Immune environment modulation in pneumonia patients
406 caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2. *Aging (Albany NY)*. 2020 May
407 2;12(9):7639–51.

- 408 38. Okabayashi T, Kariwa H, Yokota S, Iki S, Indoh T, Yokosawa N, et al. Cytokine regulation
409 in SARS coronavirus infection compared to other respiratory virus infections. *J Med Virol.* 2006
410 Apr;78(4):417–24.
- 411 39. Acharya D, Liu G, Gack MU. Dysregulation of type I interferon responses in COVID-19. *Nat*
412 *Rev Immunol.* 2020 May 26;20(7):397–8.
- 413 40. Bost P, Giladi A, Liu Y, Bendjelal Y, Xu G, David E, et al. Host-Viral Infection Maps Reveal
414 Signatures of Severe COVID-19 Patients. *Cell.* 2020 Jun 25;181(7):1475-1488.e12.
- 415 41. Boncristiani HF, Criado MF, Arruda E. Respiratory Viruses. *Encyclopedia of Microbiology.*
416 Elsevier; 2009. p. 500–18.
- 417 42. Caini S, Kroneman M, Wieggers T, El Guerche-Séblain C, Paget J. Clinical characteristics and
418 severity of influenza infections by virus type, subtype, and lineage: A systematic literature review.
419 *Influenza Other Respi Viruses.* 2018 Jul 20;12(6):780–92.
- 420 43. Jiang C, Yao X, Zhao Y, Wu J, Huang P, Pan C, et al. Comparative review of respiratory
421 diseases caused by coronaviruses and influenza A viruses during epidemic season. *Microbes Infect.*
422 2020 May 13;
- 423 44. Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19, SARS and MERS:
424 are they closely related? *Clin Microbiol Infect.* 2020 Jun;26(6):729–34.
- 425 45. Hui KPY, Cheung M-C, Perera RAPM, Ng K-C, Bui CHT, Ho JCW, et al. Tropism,
426 replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human
427 respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures. *Lancet Respir Med.*
428 2020 May 7;
- 429 46. Chu H, Chan JF-W, Yuen TT-T, Shuai H, Yuan S, Wang Y, et al. Comparative tropism,
430 replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for
431 clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study.
432 *Lancet Microbe.* 2020 May; 1(1) e14-e23
433
- 434 47. Ceccarelli M, Berretta M, Venanzi Rullo E, Nunnari G, Cacopardo B. Differences and
435 similarities between Severe Acute Respiratory Syndrome (SARS)-CoronaVirus (CoV) and SARS-
436 CoV-2. Would a rose by another name smell as sweet? *Eur Rev Med Pharmacol Sci.*
437 2020;24(5):2781–3.
- 438 48. Cameron MJ, Kelvin DJ. Cytokines, Chemokines and Their Receptors - Madame Curie
439 Bioscience Database - NCBI Bookshelf. 2013;
- 440 49. Wei C-H, Allot A, Leaman R, Lu Z. PubTator central: automated concept annotation for
441 biomedical full text articles. *Nucleic Acids Res.* 2019 Jul 2;47(W1):W587–93.
- 442 50. Waskom M, Botvinnik O, O’Kane D, Hobson P, Lukauskas S, Gemperline DC, et al.
443 Mwaskom/Seaborn: V0.8.1 (September 2017). Zenodo. 2017;

- 444 51. Wu C, Lu X, Wang X, Jin T, Cheng X, Fang S, et al. Clinical symptoms, immune factors, and
445 molecular characteristics of an adult male in Shenzhen, China infected with influenza virus H5N1. *J*
446 *Med Virol*. 2013 May;85(5):760–8.
- 447 52. Guo X-ZJ, Thomas PG. New fronts emerge in the influenza cytokine storm. *Semin*
448 *Immunopathol*. 2017 May 29;39(5):541–50.
- 449 53. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang Y-Q, et al. Lymphopenia predicts disease
450 severity of COVID-19: a descriptive and predictive study. *Signal Transduct Target Ther*. 2020 Mar
451 27;5:33.
- 452 54. Guo Y, Luan L, Patil NK, Sherwood ER. Immunobiology of the IL-15/IL-15R α complex as
453 an antitumor and antiviral agent. *Cytokine Growth Factor Rev*. 2017 Dec;38:10–21.
- 454 55. Russell CD, Unger SA, Walton M, Schwarze J. The human immune response to respiratory
455 syncytial virus infection. *Clin Microbiol Rev*. 2017;30(2):481–502.
- 456 56. Zhou J, Wang D, Gao R, Zhao B, Song J, Qi X, et al. Biological features of novel avian
457 influenza A (H7N9) virus. *Nature*. 2013 Jul 25;499(7459):500–3.
- 458 57. Wei L, Ming S, Zou B, Wu Y, Hong Z, Li Z, et al. Viral Invasion and Type I Interferon
459 Response Characterize the Immunophenotypes during COVID-19 Infection. SSRN. 2020 April;
460 <https://dx.doi.org/10.2139/ssrn.3564998>
- 461 58. Chan JFW, Lau SKP, To KKW, Cheng VCC, Woo PCY, Yuen K-Y. Middle East respiratory
462 syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. *Clin Microbiol*
463 *Rev*. 2015 Apr;28(2):465–522.
- 464 59. Mühl H. Pro-Inflammatory Signaling by IL-10 and IL-22: Bad Habit Stirred Up by
465 Interferons? *Front Immunol*. 2013 Feb 4;4:18.
- 466 60. Lauw FN, Pajkrt D, Hack CE, Kurimoto M, van Deventer SJ, van der Poll T.
467 Proinflammatory effects of IL-10 during human endotoxemia. *J Immunol*. 2000 Sep 1;165(5):2783–
468 9.
- 469 61. Drosten C, Günther S, Preiser W, van der Werf S, Brodt H-R, Becker S, et al. Identification
470 of a novel coronavirus in patients with severe acute respiratory syndrome. *N Engl J Med*. 2003 May
471 15;348(20):1967–76.
- 472 62. Peiris JSM, Lai ST, Poon LLM, Guan Y, Yam LYC, Lim W, et al. Coronavirus as a possible
473 cause of severe acute respiratory syndrome. *Lancet*. 2003 Apr 19;361(9366):1319–25.
- 474 63. van Boheemen S, de Graaf M, Lauber C, Bestebroer TM, Raj VS, Zaki AM, et al. Genomic
475 characterization of a newly discovered coronavirus associated with acute respiratory distress
476 syndrome in humans. *MBio*. 2012 Nov 20;3(6).
- 477 64. Kuiken T, Fouchier RAM, Schutten M, Rimmelzwaan GF, van Amerongen G, van Riel D, et
478 al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. *Lancet*.
479 2003 Jul 26;362(9380):263–70.

- 480 65. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and
481 consequences of cytokine storm and immunopathology. *Semin Immunopathol.* 2017 May
482 2;39(5):529–39.
- 483 66. Chien J-Y, Hsueh P-R, Cheng W-C, Yu C-J, Yang P-C. Temporal changes in
484 cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome.
485 *Respirology.* 2006 Nov;11(6):715–22.
- 486 67. Mahallawi WH, Khabour OF, Zhang Q, Makhdom HM, Suliman BA. MERS-CoV infection
487 in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. *Cytokine.* 2018 Feb
488 2;104:8–13.
- 489 68. Kim ES, Choe PG, Park WB, Oh HS, Kim EJ, Nam EY, et al. Clinical progression and
490 cytokine profiles of middle east respiratory syndrome coronavirus infection. *J Korean Med Sci.* 2016
491 Nov;31(11):1717–25.
- 492 69. Neumann G. H5N1 influenza virulence, pathogenicity and transmissibility: what do we
493 know? *Future Virol.* 2015;10(8):971–80.
- 494 70. Ramos I, Fernandez-Sesma A. Innate immunity to H5N1 influenza viruses in humans.
495 *Viruses.* 2012 Dec;4(12):3363–88.
- 496 71. Koutsakos M, Kedzierska K, Subbarao K. Immune responses to avian influenza viruses. *J*
497 *Immunol.* 2019 Jan 15;202(2):382–91.
- 498 72. Wei X-S, Wang X-R, Zhang J-C, Yang W-B, Ma W-L, Yang B-H, et al. A cluster of health
499 care workers with COVID-19 pneumonia caused by SARS-CoV-2. *J Microbiol Immunol Infect.*
500 2020 Apr 27;
- 501 73. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected
502 with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020 Feb 15;395(10223):497–506.
- 503 74. Zhou Y, Fu B, Zheng X, Wang D, Zhao C, qi Y, et al. Pathogenic T cells and inflammatory
504 monocytes incite inflammatory storm in severe COVID-19 patients. *Natl Sci Rev.* 2020 Mar 13;
- 505 75. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and Functional Exhaustion
506 of T Cells in Patients with Coronavirus Disease 2019 (COVID-19). *medRxiv.* 2020 Feb 20;doi:
507 <https://doi.org/10.1101/2020.02.18.20024364>
508
- 509 76. Eimer J, Vesterbacka J, Svensson AK, Stojanovic B, Wagrell C, Sönnnerborg A, et al.
510 Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with
511 severe COVID-19: a retrospective cohort study. *J Intern Med.* 2020 Aug 3;
- 512 77. Treveil A, Bohar B, Sudhakar P, Gul L, Csabai L, Olbei M, et al. ViralLink: An integrated
513 workflow to investigate the effect of SARS-CoV-2 on intracellular signalling and regulatory
514 pathways. *BioRxiv.* 2020 Jun 23; doi: <https://doi.org/10.1101/2020.06.23.167254>



List of **98** cytokines from relevant literature

bioRxiv medRxiv

THE PREPRINT SERVER FOR BIOLOGY THE PREPRINT SERVER FOR HEALTH SCIENCES

$n = 399$

PubTator_{Central}

$n = 5528$

search terms:

cytokine + *virus*

if no. of hits ≥ 50 :

cytokine + *virus* + *patient*

Paper matches criteria
patient data;
patient
 $n \geq 10$

False

Discard paper

True

Include and record $n = 55$


- mentioned cytokines
- direction of change


Data

Manual literature curation

medRxiv preprint doi: <https://doi.org/10.1101/2020.11.16.20203878>; this version posted November 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Number of measured cytokines






medRxiv preprint doi: <https://doi.org/10.1101/2020.11.14.20231876>; this version posted November 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.


Legend




SARS-CoV-2




H5N1



SARS-CoV



H7N9



MERS-CoV

